text:
Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir
Pavitra Roychoudhury ORCID: orcid.org/0000-0002-4567-82321,
Harshana De Silva Feelixge2,
Daniel Reeves2,
Bryan T. Mayer2,
Daniel Stone2,
Joshua T. Schiffer2,3,4 &
Keith R. Jerome1,2
RNA-guided CRISPR/Cas9 systems can be designed to mutate or excise the integrated HIV genome from latently infected cells and have therefore been proposed as a curative approach for HIV. However, most studies to date have focused on molecular clones with ideal target site recognition and do not account for target site variability observed within and between patients. For clinical success and broad applicability, guide RNA (gRNA) selection must account for circulating strain diversity and incorporate the within-host diversity of HIV.
We identified a set of gRNAs targeting HIV LTR, gag, and pol using publicly available sequences for these genes and ranked gRNAs according to global conservation across HIV-1 group M and within subtypes A–C. By considering paired and triplet combinations of gRNAs, we found triplet sets of target sites such that at least one of the gRNAs in the set was present in over 98% of all globally available sequences. We then selected 59 gRNAs from our list of highly conserved LTR target sites and evaluated in vitro activity using a loss-of-function LTR-GFP fusion reporter. We achieved efficient GFP knockdown with multiple gRNAs and found clustering of highly active gRNA target sites near the middle of the LTR. Using published deep-sequence data from HIV-infected patients, we found that globally conserved sites also had greater within-host target conservation. Lastly, we developed a mathematical model based on varying distributions of within-host HIV sequence diversity and enzyme efficacy. We used the model to estimate the number of doses required to deplete the latent reservoir and achieve functional cure thresholds. Our modeling results highlight the importance of within-host target site conservation. While increased doses may overcome low target cleavage efficiency, inadequate targeting of rare strains is predicted to lead to rebound upon cART cessation even with many doses.
Target site selection must account for global and within host viral genetic diversity. Globally conserved target sites are good starting points for design, but multiplexing is essential for depleting quasispecies and preventing viral load rebound upon therapy cessation.
Despite the success of combination antiretroviral therapy (cART) in suppressing HIV viremia, reservoirs of latently infected cells remain the major barrier for HIV cure [1]. The HIV latent reservoir is composed of long-lived infected cells harboring replication-competent proviruses with limited transcription that can reactivate and reseed the reservoir upon cART interruption [2, 3]. A promising therapeutic strategy for achieving cure involves depleting the reservoir by direct disruption of proviral genomes using engineered DNA-editing enzymes such as CRISPR/Cas9 nucleases. A growing body of research shows that endonuclease-induced mutation of essential viral genes or excision of provirus can render the virus unable to replicate [4,5,6,7,8,9,10,11,12]. If performed on a large scale, this approach could yield pharmacologically significant reservoir reduction. However, viral reservoirs are highly diverse, even in well-suppressed individuals [13, 14], and this diversity remains a major challenge for the application of genome editing strategies towards an HIV cure. Effective targeting of all viral genetic variants within an infected individual will be crucial for achieving sufficient reservoir reduction to prevent viral rebound upon cART cessation [15, 16] and preventing the emergence of resistance to this therapy [11].
Thus far, studies used to demonstrate the viability of gene-editing strategies against HIV have primarily targeted single molecular clones that provide ideal endonuclease target site recognition [7, 8]. Multiple classes of gene-editing enzymes have been studied, but the CRISPR/Cas9 system has gained popularity in recent years due to its effectiveness, relative simplicity, and ease of use. Several computational tools now exist to identify CRISPR target sites, to predict the activity of guide RNAs (gRNAs) targeting those sites, and to identify and score gRNAs based on multiple factors including predicted off-target activity [17,18,19]. However, no available tools allow guide selection based on predicted target site conservation or predicted clinical efficacy based on viral diversity. The identification and characterization of the most conserved target sites on a group- or subtype-specific basis will allow rapid selection of gRNAs when deep sequencing of a patient's reservoir is not practical or feasible. Furthermore, because the virus can evolve resistance to endonuclease targeting [11], multiple sites may need to be targeted concurrently in order to prevent the emergence of resistance. Therefore, the selection of multiplexed sets of gRNAs must account for the diversity of circulating strains across a wide range of infected people, and dosing strategies must consider within-host diversity of HIV to maximize the probability of a functional cure.
Here, we present a CRISPR gRNA design strategy that selects target sites not only by predicted efficacy and specificity but also by prevalence in the population. We first created a database of highly conserved target sites in HIV LTR, gag, and pol focusing on group- and subtype-level conservation using information about the global sequence diversity of HIV. We used this database to identify highly conserved target site pairs and triplets to create multiplex gRNA designs predicted to maximize targeting and reduce the probability of treatment resistance. From this analysis, we identified and tested 59 LTR guides using a fluorescent reporter to quantify activity in vitro. We then used deep-sequence data from HIV-infected individuals to determine within-host target site conservation and probability of cleavage by individual gRNAs in our list. Finally, we used a mathematical model to predict the number of doses that would be required to achieve functional cure thresholds, while accounting for varying levels of target site diversity and enzyme efficacy.
Broadly targeting spCas9 gRNAs against HIV gag, pol, and LTR
We performed a screen to identify globally conserved target sites for Streptococcus pyogenes (spCas9) in LTR, gag, and pol using alignments for these regions obtained from the HIV LANL database. LTR was chosen for its utility in excision of the provirus [8, 20, 21], while gag and pol were chosen based on their conservation between HIV strains [22]. The publicly available LANL alignments contain HIV sequences from thousands of infected persons (from about 1200 for LTR to more than 8000 for pol) and include strain and geographic information. From these alignments, we computed majority consensus sequences for LTR, gag, and pol of HIV-1 group M and subtypes A–C. We identified a total of 246 unique gRNA target sites in LTR, 573 in gag, and 897 in pol. For each target site identified, we determined the number of exact hits in the overall alignment of all group M sequences and for each subtype and ranked target sites by overall prevalence (Fig. 1). Target sites were found to be most conserved in pol (Table 1), where a single target site was present in up to 86.5% (n = 4416) of all group M sequences. The most conserved target sites in LTR and gag occurred in up to 70.6% (n = 1216) and 71.1% (n = 8435), respectively, of group M sequences.
Top 100 gRNA target sites in HIV LTR (a), gag (b), and pol (c) ranked by prevalence (bottom to top) within an alignment of available sequences within group M for each genomic region. The x-axis shows the percentage of all sequences in group M that contain an exact match to the target site. Within each horizontal bar, shading indicates what percentage of sequences with target sites hits belong to each subtype. Inset bar plots show the total number of sequences of each subtype in the alignment
Table 1 Maximum targeting possible with 1, 2, or 3 gRNAs
We determined predicted on-target cleavage efficiency and off-target activity for each guide sequence (Fig. 2) using the sgRNA designer tool [17]. Predicted on-target activity scores were in the range [0,1] where a score of 1 was associated with successful knockout in the experiments of Doench et al. [17, 23] and gRNAs with scores < 0.2 were generally excluded because they were shown to be predictive of poor activity. Mean predicted activity scores across all identified guides were 0.50 (SD 0.12, n = 246) for LTR, 0.49 (SD 0.13, n = 573) for gag, and 0.47 (SD 0.13, n = 897) for pol. From the list of gRNAs identified, we excluded 10 from gag and 26 from pol from further analyses due to high predicted off-target activity scores. No significant correlation was observed between predicted activity and target site conservation (Additional file 1: Table S1A).
a Histogram of predicted activity of all gRNAs identified in LTR, gag, and pol across all four consensus sequences (group M, subtypes A–C) for each gene. b Predicted activity score vs. target site conservation for individual gRNAs grouped by subtype and gene. Red triangles indicate gRNAs excluded due to predicted off-target activity. Numbers in blue represent the total number of guides with predicted activity score > 0.2 and where target sites occur in more than 50% of sequences in the group or subtype alignment
Multiplexed gRNA designs
For each gene, we determined the number of sequences that could be targeted by pairs and triplets of gRNAs in group M overall, and in each subtypes A–C (Table 1). We determined that just two strategically selected gRNAs are sufficient for targeting 100% of LTR and pol sequences in the current global alignment for subtype A, and three gRNAs are able to target over 98% of all sequences in subtypes A–C. However, when considering all group M sequences, the maximum percentage of sequences targeted by triplet sets of gRNAs drops to 88.8% for LTR, 95.5% for gag, and 99.2% for pol (Table 1 and Additional file 1: Table S2). The two most conserved LTR sites in the whole of group M (ranks 1 and 2) were also the most prevalent target sites in the individual subtypes, but this was not the case for gag and pol (Additional file 1: Table S2).
Overall, better coverage of group M or subtypes A–C sequences was achieved when pair or triplet gRNAs targeted pol, suggesting that pol is an ideal therapeutic target for targeted mutagenesis with multiplexed guide RNAs. We determined that a minimum set of eight gRNA target sites would be required to guarantee that every pol sequence in the group M global was targeted at least once.
Functional testing of selected gRNAs
From our list of 246 gRNAs targeting LTR, we identified 59 gRNAs for functional testing by first considering the most conserved target sites in group M and each subtype. We then included any gRNAs that increase the number of sequences targeted when combined in pairs or triplets with the previous list (Additional file 2: Figure S1A). In order to test the activity of these guides in vitro, we designed LTR-GFP fusion reporter constructs using consensus sequences for group M and subtypes A–C (Fig. 3a, Additional file 2: Figure S1B). We tested the ability of each gRNA to knock down reporter GFP expression in HEK293 cells following co-transfection with a plasmid expressing spCas9 mCherry containing each HIV-specific gRNA and the LTR-GFP fusion reporter. The activity of each gRNA was measured in terms of percent knockdown of median GFP fluorescence intensity relative to negative controls at 24 h post-transfection in Cas9 expressing (mCherry positive, Additional file 2: Figure S1C) cells.
a LTR-GFP fusion reporter to test gRNAs for activity in vitro. b Activity was measured in terms of percent knockdown of median GFP fluorescence intensity relative to negative controls. We found positive but statistically non-significant correlation between computationally predicted activity scores and measured activity. c We achieved reduction of GFP fluorescence intensity (positive activity) with a majority of gRNA designs and observed clustering of tested target sites in two areas of the LTR with the most active guides being clustered around the center of the LTR. With a small number of gRNAs, we observed negative activity (increase in GFP fluorescence). Lower panel shows residue conservation (in 0–2 bits) across the LTR for alignments of subtype sequences or all sequences in group M
We compared measured gRNA activity to predicted activity scores from the sgRNA designer (Fig. 3b); there was a trend towards weak positive correlation between predicted and measured activity (Pearson's r = 0.25, n = 59, 95% CI = 0.00–0.48, Additional file 1: Table S1B). We observed a reduction of GFP fluorescence intensity with 52 out of 59 gRNAs (Fig. 3c, Additional file 1: Table S4), with a maximum knockdown of 76.3% (mean = 15.3%, SD = 16.0%, n = 59). Maximum knockdown was achieved at target site CAAAGACTGCTGACACAGAAGGG, which was identified in the consensus sequence of subtype C and found to occur in 23.1% of group M sequences and 68.4% of subtype C sequences in the 2016 LANL alignment. We observed clustering of the most active guides within the LTR; target sites for gRNAs with GFP knockdown > 30% were found at positions 74–75, 319–344, and 446 relative to the start of the 5′ LTR. Although some active guides appear to coincide with regions of high-residue conservation within the LTR (Fig. 3c), we found no significant correlation between GFP knockdown and target site prevalence within all available sequences in Group M (Pearson's r = − 0.03, n = 59, 95% CI = − 0.28–0.23, Additional file 1: Table S1C).
In silico testing of candidate gRNAs on within-host patient sequences
In order to simulate the application of this gene-editing approach on a diverse within-host virus population, we used a published dataset of HIV sequences obtained from HIV-infected blood donors in Brazil [24], focusing on the pol gene (because it is the most highly conserved) for 10 patients. We started with our list of all pol target sites that we identified above from group and subtype consensus sequences from 2016 LANL alignments, labeling each target site according to the consensus sequence it was identified from (300, 317, 304, and 328 target sites from group M and subtype A–C consensus sequences, respectively, 1249 sites total, 897 unique sites). From this combined list of globally conserved target sites, we determined whether each site was present in each patient's HIV consensus sequence (Additional file 1: Tables S5 and S6) [24]. Across infected persons, an average of 89.4 group M target sites (i.e., 29.80% of all group M sites identified) and 119.9 subtype B sites (39.44% of all subtype B target sites identified) were found to be also present within patient consensus sequences (SD 11.14 sites/3.24% and 9.84 sites/3.71%, respectively, n = 10 patients), while subtype A and C sites were identified less frequently (Fig. 4a). Since subtype B is highly prevalent in Brazil, this was not surprising. Five target sites were found to be present in all 10 patient consensus sequences (Additional file 1: Table S6), and one of these (GATGGCAGGTGATGATTGTGTGG) was also highly conserved in the global alignment for subtype B (present in 87.09% of LANL sequences). These five target sites were found to occur between positions 2294 and 2981 in pol. In addition, we identified gRNA target sites directly from the patient's consensus sequence. The number of directly identified sites for each patient ranged between 276 and 313 (mean = 299.30, SD = 10.83, n = 10). Out of 1712 unique sites generated from the 10 patients' consensus sequences, 351 were present in our list of globally conserved sites. Of the remaining sites, 1135 were only present in a single individual and 87 sites were found in more than 5 individuals. With one exception (GTTTCTTGCCCTGTCTCTGCTGG), every site that was present in more than 5 individuals was also present in our global list.
a Number of previously identified target sites from global consensus sequences of group M and subtypes A–C that were present in each patient's HIV consensus sequence. b Within-host target site conservation for each identified target site using deep-sequence data for 4 patients, summarized using box plots. Black dots indicate outlier target sites (outside 1.5 × IQR), and target sites are grouped and colored according to which consensus sequence they were identified from (the group- or subtype-level consensus from LANL alignments, or from the patient's HIV consensus sequence)
Next, we used deep-sequence data from each of these individuals [24] to determine the degree of conservation of each target site within the patient's virus quasispecies population. In order to accurately quantify rare target site variants, we identified 4 out of 10 patient datasets where mean coverage across all identified target sites was above 5000× (Additional file 1: Table S2, Additional file 3: Figure S2B). For each of these patients, we determined within-host target site conservation by computing the percentage of reads in the alignment containing an exact match to the site. Within-host target site conservation was found to vary dramatically for individual gRNAs and between individual patients, ranging between 5.5 and 95.6% with a mean of 83.5% (SD 14.3%, n = 2298) (Fig. 4b).
Within-host target site conservation was an average of 3.4% higher for sites identified from our global list (range of means = 84.7–86.5%, n = 4 patients) compared to sites that were only present in the patient's sequence (mean = 81.6%, n = 4, p = 0.026), but the difference between groups was not statistically significant (F test, p = 0.15). Target sites identified from group M or subtype B consensus sequences tended to be more conserved than sites identified from the patient sequence, but the differences were not statistically significant (both 3.7% higher, with p = 0.087 and p = 0.054, respectively). Within-host target site conservation was nearly identical using group M or subtype B sites (p = 0.98). All p values were > 0.1 after multiple test corrections.
Modeling reservoir depletion with CRISPR-based therapy
We developed a mathematical model to understand the effect of experimentally controllable parameters on reservoir depletion with hypothetical weekly dosing of various candidate CRISPR/Cas9 therapies targeting HIV. The model simulates the clearance of the latent reservoir by including many (up to 104) quasispecies carrying replication-competent DNA. These species are unevenly abundant and are assumed to follow a log-normal distribution so that each quasispecies contains 1–1000 members. Further, each quasispecies is cleared from the reservoir so that the total reservoir clearance rate recapitulates the experimentally measured reservoir half-life of 3–4 years [25, 26]. In the absence of CRISPR therapy, the model simulates a fluctuating but, on average, slowly decaying HIV reservoir with varying compositions [27]. We then simulated reservoir clearance with varying enzyme efficacy (ϵ, the probability of successful mutagenic DNA cleavage at the target site) and varying coverage proportion (ρ, the proportion of sequences that would respond to enzyme). The measure of target site conservation was based on our analysis of patient samples. Parameter ranges for ϵ were based on ranges of predicted cleavage efficiency from the sgRNA designer tool (Fig. 2) and measured activity (Fig. 3) described above.
Including CRISPR, our simulations suggest that treatments with gRNAs targeting a single site will be insufficient to achieve functional cure even at high levels of target site conservation and enzyme efficacy (Fig. 5a, Additional file 4: Figure S3). Enzyme efficacy is relatively unimportant in this case, only affecting the number of treatments needed to remove the sensitive quasispecies. Once removed, additional treatments provide no additional benefit and insensitive quasispecies dominate the reservoir (Fig. 5a). However, if 100% coverage of all quasispecies can be achieved through the selection of a multiplexed set of gRNAs that can be delivered simultaneously, the number of treatments to deplete the reservoir to the first cure threshold (100-fold decrease [16]) can be achieved in 1–5 treatments depending on efficacy (Fig. 5c), whereas the second threshold (2000-fold decrease [15]) may require 5–10 treatments depending on efficacy. For all modeled assumptions, coverage is vital to reservoir depletion. Whereas suboptimal efficiency can be surmounted by repeated doses, the diversity of the reservoir constitutes the largest barrier to depletion.
Simulated reservoir depletion with anti-HIV CRISPR therapy. a Example simulation based on predicted target site conservation ("potency," ρ = 0.5) and enzyme efficacy to each target site (ϵ = 0.5). CRISPR therapy is dosed weekly, and the average strain contains 100 infected cells (μs = 100). Thin colored lines represent single strains, Ls(t), and the thick black line represents the total reservoir, L(t) = ∑sLs(t). Strains targeted by CRISPR are cleared rapidly, but untargeted strains remain unaffected and the total reservoir size does not decrease below estimated depletion thresholds for functional cure. The dashed line represents a stringent threshold for latent reservoir reduction where patients are expected to remain suppressed for years without cART [15, 16]. See Additional file 4: Figure S3 for simulations varying all parameters. b If 100% coverage (ρ = 1) of target sites can be achieved (either through multiplexing of targets or due to a target site that is highly conserved), enzyme efficacy becomes relevant, dictating the number of doses to cure. At or better than predicted efficacy ϵ > 0.5, doses range between 1 and 5 doses for a median 1 year remission and 5–10 doses for a potentially lifelong absence of viral rebound based on previously estimated thresholds. However, even for 100% coverage, efficacy at 10% or less per dose requires substantial dosing (> 30) to achieve thresholds
Gene editing using CRISPR/Cas9 has the potential to effect a functional cure for HIV through targeted mutagenesis or proviral genome excision [28]. This approach has now been demonstrated in multiple proof-of-concept in vitro and in vivo studies [7, 9,10,11,12, 20, 29, 30]. While laboratory demonstration of gRNA activity has largely relied on clonal populations of lab-adapted HIV strains, clinical applications of this method will need to consider the wide intra- and inter-host diversity of HIV. The global diversity of HIV-1 is reflected in the classification of viruses into four broad groups (M, N, O, and P) that are 25–40% divergent, and within-group subtypes that are up to 15% divergent [22]. This remarkable global diversity of HIV is the result of within-host evolution and adaption to immune pressure, and transmission of genetic variants from the host quasispecies over multiple rounds of viral replication. Target sites chosen for gene editing will therefore also need to reflect this genetic variability within and between individuals.
Globally conserved target sites are good starting points for gRNA design; if their high frequencies in the population are the result of selection, endonuclease-induced mutations are more likely to be highly deleterious to the virus. Indeed, it has been shown that highly conserved target sites are associated with improved antiviral activity and, importantly, delayed viral escape [10, 29]. Identification of sites that are conserved at a global or subtype level may also allow for future deployment of these therapies in situations where obtaining individual patient HIV sequence data may not be feasible or practical. To this end, we identified gRNA target sites in HIV LTR that were highly conserved in global consensus sequences and tested the activity of these guides in vitro. Using a separate set of deep-sequence data [24], we showed that sites identified from our list of globally conserved targets that were present in the patient's sequence also showed greater within-host conservation. For computational efficiency, our approach looks for exact matches, but future enhancements could incorporate position-dependent penalties to account for the ability of Cas9 to bind in the presence of mismatches to the target site.
The experimental setup used to test candidate gRNAs was designed to allow us to compare gRNAs against each other while minimizing the confounding factors such as cell line-derived variation. We performed the assays under low transfection efficiency conditions and gated on mCherry-positive cells in order to limit plasmid copy numbers that could affect the ability to observe changes in GFP fluorescence intensity by flow cytometry. Since we have previously seen variations in transfection efficiency between different target site reporter plasmids when transfected under the same conditions, we incorporated two internal GFP-specific gRNAs as controls to be analyzed with each reporter. This allowed us to compare the relative activity across all of the LTR-specific gRNAs since they could not all be tested against each of the LTR reporters. We found that within the described transfection efficiency range, we saw comparable levels of relative GFP knockdown when using the two GFP control gRNAs.
Gene therapy approaches designed to cure an infected individual will need to ensure that all relevant within-host variants are targeted. Although early initiation of long-term cART has been shown to reduce the rate of HIV evolution, the virus is still thought to accumulate about 0.97 mutations/kb/year [13, 14]. Using a mathematical model, we showed that variants that are not recognized and cleaved will be the major barrier to achieving functional cure thresholds. These variants, if replication-competent, have the potential to reactivate upon cART interruption and reseed the reservoir. Our model makes assumptions about the underlying distribution of quasispecies abundance, which is not fully understood. Yet, because CRISPR works on a fraction of quasispecies, our conclusions appear robust to simulated reservoirs with different absolute number of species (see Additional file 4: Figure S3). Estimating time to rebound based on reservoir reduction is challenging and various estimates of thresholds for depletion exist [15, 16, 31,32,33]. In our simulations, we have included estimates for median 1 year and median lifetime remission from HIV rebound [15, 16]. These thresholds were developed from natural reservoirs and might not correspond exactly to the perturbed CRISPR-treated reservoirs. Most importantly, the depletion itself depends on targeting viral quasispecies diversity. While we endeavor to estimate targeting proportions in the present work, further experiments are needed to fully understand the in vivo process.
Besides cleavage efficiency, target site conservation, and reservoir size, a number of other factors will also contribute to the clinical success of this type of gene therapy for HIV cure [28, 34,35,36]. For example, we have also not explicitly incorporated gene delivery in the current model but instead assumed that it is captured within the cleavage efficiency parameter ϵ. However, we have shown previously [37] that gene delivery of endonucleases using viral vectors is prone to large bottlenecks at the points of vector packaging, viral entry, and gene expression. Optimization of gene delivery is therefore another important step needed for the clinical success of gene therapies against HIV. We and others have shown that multiple doses will be needed to deplete the reservoir to achieve functional cure thresholds [15, 16, 37]. Dosing regimens will need to optimize efficacy while minimizing potential toxicity and off-target effects.
HIV has also been shown to rapidly escape endonuclease targeting in vitro [10, 11, 29]. Although this risk is reduced by keeping the patient on cART, it is still important for endonuclease-based therapies to target multiple sites concurrently in order to achieve sustained reservoir depletion and prevent the emergence of treatment resistance. Our simulations support these findings and show that even enzymes with high on-target efficiency will fail to produce a functional cure if there are target site variants present at frequencies as low as 1%. Two recent proof-of-principle studies showed that an approach with dual gRNAs targeting multiple genes can delay or completely prevent viral escape [12, 38]. We identified paired and triplet sets of gRNA target sites that occur in over 98% of the population. Since these sites are likely to also be highly conserved within-host (as our results suggest), they would be good candidates for testing in vitro for activity. Although our mathematical model can incorporate multiplexed gRNAs by changing the coverage (ρ), it does not explicitly include dynamic emergence of treatment-resistant variants. Our model framework is amenable to emergent resistance but was not included for lack of information on these dynamics. Nor does the model include potential anatomic sanctuary sites where HIV diversity changes in time. The modeled CRISPR therapy assumes constant suppressive cART, and we rely on previous observations that potent cART prevents most ongoing evolution [13, 39,40,41,42,43].
A number of recent studies have designed LTR-based CRISPR strategies and shown broad antiviral activity against HIV in a number of different model systems [7, 8, 12, 20, 21, 38, 44, 45]. LTR is an attractive target because there are two copies per provirus genome, and this allows a single gRNA to potentially cleave two independent regions, leading to a deletion of a majority of the provirus or mutations in one or both LTRs. Each of these potential outcomes is beneficial as they can all impact HIV replication and reactivation. However, we have shown here that pol may be a better genomic target for directed mutagenesis due to target site conservation, which allows targeting of a majority of variants with reasonable numbers of gRNAs in multiplexed designs. As a result, we believe that targeting multiple sites within pol may be a better approach than targeting LTR alone, which generally contains less conserved sites.
The weak correlation between predicted and measured activity scores is likely due to differences in the methods, cell lines, and experimental conditions used to generate the two sets of scores. The predicted activity score generated by the sgRNA designer tool is based on a broad genome-wide CRISPR-based screen that was used to train a machine learning model [17]. In spite of the differences in approaches, the fact that the scores are correlated is encouraging because it helps to further validate this broadly used metric.
One of the limitations of our within-host analysis is that we do not have detailed information about the patient cohort [24] such as treatment status, age at HIV diagnosis, and time of cART initiation and interruption, if any. These factors could potentially impact reservoir diversity. However, the current analysis is primarily aimed at demonstrating the importance and feasibility of designing gRNAs targeting a diverse viral population. Future work needs to address this in greater detail, possibly incorporating treatment-related variables to select gRNA designs.
In summary, we have performed a detailed computational analysis to identify optimal CRISPR target sites, taking into consideration both within-host and global viral diversity. We determined the in vitro activity of a set of gRNAs targeting highly conserved sites and showed a weak but positive correlation between measured and predicted activity. We used a mathematical model to simulate clinical application of this therapy and showed that although increased dose may overcome low target cleavage efficiency, inadequate targeting of rare strains is predicted to lead to rebound upon cART cessation even with many doses. Our results have applications beyond HIV and CRISPR since genetic diversity is an important consideration for any gene therapy platform targeting a heterogeneous population, whether it is a persistent viral disease such as hepatitis B virus, or even cancer.
HIV sequence datasets and pre-processing
For our analysis of global target site conservation, we obtained sequences from the Los Alamos National Laboratory (LANL) database. For each region of interest (gag, pol, LTR), we downloaded pre-made LANL alignments of all available group M sequences (2016 version). We extracted a majority consensus sequence using Geneious v10 [46] for all sequences in group M and for each subtype. We did not consider groups N, O, or P in our analyses because they represent a small fraction of HIV infections globally compared to group M and there are limited sequences available for these groups. However, our algorithms are easily adapted to run on any alignment provided.
For within-host analyses of target site conservation, we used deep-sequencing data (Additional file 1: Table S5) from a study of HIV-infected blood donors in Brazil [24]. Raw paired-end reads for each patient were trimmed to remove adapters and low-quality regions using Trimmomatic v0.32.2 [47] and mapped using Bowtie2 v0.2 [48] to the consensus sequence deposited by the authors to GenBank. These pre-processing steps (Additional file 3: Figure S2) were performed within the Galaxy software framework (https://galaxyproject.org/).
gRNA target site analysis
We developed a custom script to identify gRNA target sites for an input sequence given a specified PAM sequence (default 'NGG' for spCas9) and desired gRNA length w (default 20 nt). The algorithm finds all matches to the PAM sequence in the forward and reverse directions and returns, for each match, w bases upstream of the PAM sequence. We then used the sgRNA designer from the Broad Institute (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) to determine predicted on-target efficacy score and off-target scores (threat matrix) [17]. On-target predicted activity scores are in the range [0,1] with higher values predicting more active guides and a score of 1 indicating successful knockout in the experiments in [17, 23].
For each target site identified, we determined the number of exact matches found in an alignment of the region of interest (LTR, gag, or pol). We excluded all sites with close off-target matches to the human genome (> 3 matches in Match Bin I, i.e., CFD score = 1 [17]). For each region, we determined pairs and triplets of gRNAs by starting with the previously identified list of gRNAs and adding on guides that increase targeting when used in combination.
We computed target site conservation in terms of the frequency of occurrence of the target site (exact matches) within the alignment and also we used a measure of information content similar to what is used to generate sequence logo plots [49, 50]. We applied a moving window of size 23 (corresponding to the width of gRNA) and computed conservation from the relative frequencies of bases in the alignment using the method of Schneider et al. [50] incorporating small-sample correction. The result is a value between 0 and 2 bits with higher values indicating greater sequence conservation. All analyses were performed in R/Bioconductor, and code is available on GitHub (http://github.com/proychou/CRISPR).
Functional testing of gRNA activity
Starting with the list of target sites identified above in LTR, we selected gRNAs from a pool of the top 20 most conserved sites across group M overall, the top 10 most conserved sites in each subtype, and the top 20 pairs and triplets. As recommended by sgRNA designer, we excluded any gRNAs with on-target activity scores < 0.2.
We developed 4 LTR-GFP fusion reporter constructs using consensus sequences for all group M, subtype A, subtype B, and subtype C (further details in Additional file 5). Internal start codons and stop codons were identified within the sequence for each consensus LTR, and the reading frame with the fewest combined number of start codons and stop codons was identified. Reading frame 1 for group M contained 5 start and 4 stop codons, reading frame 1 for subtype A contained 3 start and 6 stop codons, reading frame 1 for subtype B contained 3 start and 6 stop codons, and reading frame 1 for subtype C contained 3 start and 5 stop codons. All the internal start and stop codons were modified for each consensus LTR sequence as follows: ATG to GTG - M to V; TGA to GGA - stop to G; TAG to GAG - stop to E; TAA to GAA - stop to E, so that one continuous open reading frame was generated. Each of the 4 modified consensus LTR sequences was then synthesized as a gBlock and cloned into a reporter plasmid vector (cloning details available upon request) as a fusion to the 5′ end of the eGFP ORF so that the MND promoter drove expression of a single continuous ORF (see Additional file 2: Figure S1A for amino acid sequences). The majority of the 59 gRNA target sites identified for analysis within the group M, subtype A, subtype B, and subtype C consensus LTRs were not changed by start or stop codon modification, with the exception of overlapping gRNA targets 1 and 2, and overlapping gRNA targets 18 and 19. A separate reporter construct was generated for gRNAs 1, 2, 18, and 19 by fusing their target sequences to the 5′ end of the eGFP ORF so that the MND promoter also drove expression of a single continuous ORF (cloning details available upon request).
Of the 59 LTR-specific gRNA target sites we elected to screen for activity, 23 were present in the group M reporter, 27 were present in the group A reporter, 20 were present in the group B reporter, 18 were present in the group C reporter, and gRNAs 1, 2, 18, and 19 were not present in any LTR reporter. Three of the gRNA targets were present in all 4 LTR-reporter constructs, 8 were present in 3 LTR-reporter constructs, and 8 were present in 2 LTR-reporter constructs. To screen the activity of individual LTR-specific gRNAs, they were cloned into the BbsI site of the plasmid pU6-(Bbs1) CBh-Cas9-T2A-mCherry (a gift from Ralf Kuehn; Addgene plasmid no. 64324) under the control of the U6 promoter. This plasmid expresses spCas9 and mCherry from the constitutive CBh promoter. Internal positive controls for GFP knockdown were used by also cloning gRNAs eGFP1 and eGFP2 targeting the sequences CAACTACAAGACCCGCGCCG and GTGAACCGCATCGAGCTGAA into pU6-(Bbs1) CBh-Cas9-T2A-mCherry. To assay gRNA activity 2 × 105, 293 cells were plated in 12-well plates and the following day individual wells were transfected by PEI transfection with 1000 ng of a Cas9/LTR-gRNA expressing plasmid and 250 ng of its corresponding LTR-reporter plasmid. At 24 h post-transfection, flow cytometry was performed and GFP fluorescence was analyzed in Cas9 expressing (mCherry positive) 293 cells to determine the level of GFP knockdown provided by each gRNA.
Analysis of flow cytometry data
Raw fcs files were gated using functions from the OpenCyto framework in R/Bioconductor [51] as described previously [37]. Flow data has been uploaded to FlowRepository (https://flowrepository.org/id/FR-FCM-ZYHR), and code is available at http://github.com/proychou/CRISPR.
Intra-host target site conservation
Focusing on the pol gene, we identified spCas9 gRNA target sites within the HIV consensus sequence for each patient using the script described above, excluding any sites containing degenerate bases. We also determined which of the target sites we had previously identified from group- and subtype-level consensus sequences for pol were present in the patient consensus sequence. Using the average number of reads overlapping all identified target sites, we excluded any patients with < 5000× target site depth since we were interested in variants that may escape targeting by candidate gRNAs. For each target site, we determined the number of reads in the alignment containing an exact match to the target site and excluded any sites where coverage was less than 5000×. We then used the total number of reads that completely overlap the target site to calculate the percentage of exact target site matches.
Statistical analysis of within-host conservation
To test whether there were differences in target site conservation measured by mean percentages of exact target site matches per total reads, a linear mixed model was fit with percentage as the outcome and the consensus sequence group (group M, subtypes A–C, and patient) as the predictors. A random intercept for each subject by consensus group was used to account for within subject and group variation across the repeated outcomes. An overall test was performed from ANOVA for mixed models using the lmerTest package in R [52]. Post-hoc pairwise tests were also performed comparing the patient-derived sequences, group M, and subtype B (the circulating strain in the patient population). To compare the conservation using patient target sites to the consensus groups, we pooled group M and subtypes A–C into a single group for comparison in the model, while the random effects specification remained the same. P values corrected for multiple testing were also reported using the Holm method [53]. Code and data are available at http://github.com/proychou/CRISPR.
Mathematical model of reservoir depletion with simultaneous suppressive cART and CRISPR therapy
We have used a mathematical model to describe natural clearance of the HIV reservoir on consistent cART previously [27]. That model assumed an HIV reservoir that exponentially cleared with previously measured rates. Here, we extended that model to consider simultaneous treatment with suppressive cART and CRISPR gene therapy. The reservoir is now conceived of as a population of different strains, and each strain is associated with some number of infected cells. cART is assumed to prevent ongoing replication, viral evolution, and/or increases of diversity. Additional CRISPR therapy targets some fraction of these strains, and depending on the coverage, or "proportion" (ρ), and the enzyme activity to those covered strains, or "efficacy" (ϵ), the reservoir is reduced accordingly with each successive CRISPR dose. Throughout the simulations, we use weekly doses τ = 7 days, but this choice is arbitrary and adjustable.
The natural clearance of the reservoir on suppressive cART was modeled as follows. For each strain, a clearance rate was randomly sampled so that the clearance of the entire reservoir agrees with previously measured population level statistics [25, 26] such that the half-life of latently infected cells is normally distributed with mean and standard deviation of 3.6 and 1.5 years, respectively, or \( {t}_{\left\{1/2\right\}}\sim \mathcal{N}\left(\mathrm{3.6,1.5}\right) \). Of note, this half-life represents the natural clearance rate of the replication-competent reservoir as measured by viral outgrowth assays [25, 26]. In contrast, the half-life of HIV DNA is longer [54, 55]. We call the strain-specific clearance rate θs (per day). Each strain (indexed by s) is initialized with a number of infected cells Ls(0) drawn from a log-normal distribution with average value μs and standard deviation σs = μs so that each strain has size \( \log {L}_s(0)\sim \mathcal{N}\left({\mu}_s,{\sigma}_s\right) \). Then, we denote the total number of strains \( \mathcal{S} \) and the total initial reservoir size L(0) that \( \sum \limits_{s=1}^{\mathcal{S}\ }{L}_s(0)=L(0) \). The total number of strains is constrained by the initial reservoir size as \( \mathcal{S}\approx L(0)/{\mu}_s \).
We can write model for a single strain without CRISPR therapy using an ordinary differential equation (ODE) model as \( \dot{L_s}=-{\theta}_s{L}_s \), where the over-dot denotes derivative in time. Such an equation is solved simply, Ls(t) = Ls(0) exp(−θst), and applies for strains not in the covered CRISPR set, (s ∉ ∁), where \( \complement =\left\{1,2,3,\dots |\rho \mathcal{S}|\right\} \) and |·| denotes rounding to the nearest integer. For strains in the CRISPR set, the dynamics are governed by the additional reduction in reservoir due to CRISPR, η(t, τ), such that the CRISPR instantaneously removes a fraction of the reservoir ϵLs(t) after each dosing time τ. We solve these equations accordingly for strains in and not in the covered set and sum to find the total reservoir size L(t) = ∑sLs(t). Stochastic simulations and deterministic simulations result in similar results (data not shown). All code is freely available at http://github.com/proychou/CRISPR.
Parameters relating to CRISPR (ϵ, ρ, μs) are varied throughout simulations. The reservoir initial size was held constant throughout simulations at ~ 1 million cells [25, 26, 56]. The clearance rate of each strain was sampled from a normal distribution with mean half-life 3.6 years and standard deviation 1.5 years as has been measured previously [26]. In the stochastic simulation, strains do sometimes increase over time on cART, a realistic phenomenon. However, simulations were also performed with clearance rates of zero to similar results. Indeed, based on the timeframe of the present analyses (less than a year of cART), natural clearance has a minimal impact compared to CRISPR intervention.
Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science (80- ). 2009;323:1304–7. https://doi.org/10.1126/science.1165706.
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900. https://doi.org/10.1038/nm.1972.
Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JAD, et al. Peripheral Vγ9Vδ2 T cells are a novel reservoir of latent HIV infection. PLoS Pathog. 2015;11 https://doi.org/10.1371/journal.ppat.1005201.
Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science (80- ). 2007;316:1912–5. https://doi.org/10.1126/science.1141453.
Mariyanna L, Priyadarshini P, Hofmann-Sieber H, Krepstakies M, Walz N, Grundhoff A, et al. Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One. 2012;7 https://doi.org/10.1371/journal.pone.0031576.
Qu X, Wang P, Ding D, Li L, Wang H, Ma L, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 2013;41:7771–82. https://doi.org/10.1093/nar/gkt571.
Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013;3:2510. https://doi.org/10.1038/srep02510.
Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014;111:11461–6. https://doi.org/10.1073/pnas.1405186111.
Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology. 2015;12:22. https://doi.org/10.1186/s12977-015-0150-z.
Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, et al. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep. 2016;15:481–9. https://doi.org/10.1016/j.celrep.2016.03.042.
De Silva Feelixge HS, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, et al. Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antivir Res. 2016;126:90–8. https://doi.org/10.1016/j.antiviral.2015.12.007.
Wang G, Zhao N, Berkhout B, Das AT. A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures. Cell Rep ElsevierCompany. 2016;17:2819–26. https://doi.org/10.1016/j.celrep.2016.11.057.
Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci. 2013;110:E4987–96. https://doi.org/10.1073/pnas.1308313110.
Dampier W, Nonnemacher MR, Mell J, Earl J, Ehrlich GD, Pirrone V, et al. HIV-1 genetic variation resulting in the development of new quasispecies continues to be encountered in the peripheral blood of well-suppressed patients. PLoS One. 2016;11 https://doi.org/10.1371/journal.pone.0155382.
Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2014;111:13475–80. https://doi.org/10.1073/pnas.1406663111.
Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, et al. HIV reactivation from latency after treatment interruption occurs on average every 5-8 days—implications for HIV remission. PLoS Pathog. 2015;11:e1005000. https://doi.org/10.1371/journal.ppat.1005000.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184–91. https://doi.org/10.1038/nbt.3437. Nature Publishing Group
Xie S, Shen B, Zhang C, Huang X, Zhang Y. sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites. PLoS One. 2014;9:e100448. https://doi.org/10.1371/journal.pone.0100448. Khodursky AB, editor
Zhu LJ. Overview of guide RNA design tools for CRISPR-Cas9 genome editing technology. Front Biol (Beijing). 2015;10:289–96. https://doi.org/10.1007/s11515-015-1366-y.
Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE, et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 2016:1–6. https://doi.org/10.1038/gt.2016.41.
Yin C, Zhang T, Li F, Yang F, Putatunda R, Young W-B, et al. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS. 2016;30:1163–74. https://doi.org/10.1097/QAD.0000000000001079.
Li G, Piampongsant S, Faria NR, Voet A, Pineda-Peña A-C, Khouri R, et al. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology. 2015;12:18. https://doi.org/10.1186/s12977-015-0148-6.
Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation. Nat Biotechnol. 2014;32:1262–7. https://doi.org/10.1038/nbt.3026. Nature Publishing Group
Pessôa R, Loureiro P, Esther Lopes M, Carneiro-Proietti ABF, Sabino EC, Busch MP, et al. Ultra-deep sequencing of HIV-1 near full-length and partial proviral genomes reveals high genetic diversity among Brazilian blood donors. PLoS One. 2016;11:e0152499. https://doi.org/10.1371/journal.pone.0152499. Kaderali L, editor
Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–8. https://doi.org/10.1038/nm880.
Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JAD, et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis. 2015;212:1361–5. https://doi.org/10.1093/infdis/jiv218.
Reeves DB, Duke ER, Hughes SM, Prlic M, Hladik F, Schiffer JT. Anti-proliferative therapy for HIV cure: a compound interest approach. Sci Rep. 2017;7:4011. https://doi.org/10.1038/s41598-017-04160-3.
Spragg C, De Silva Feelixge H, Jerome KR. Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS. 2016;11:442–9. https://doi.org/10.1097/COH.0000000000000284.
Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther. 2016;24:522–6. https://doi.org/10.1038/mt.2016.24.
Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, et al. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep. 2016; https://doi.org/10.1038/srep22555.
Pinkevych M, Kent SJ, Tolstrup M, Lewin SR, Cooper DA, Søgaard OS, et al. Modeling of experimental data supports HIV reactivation from latency after treatment interruption on average once every 5–8 days. PLOS Pathog. 2016;12:e1005740. https://doi.org/10.1371/journal.ppat.1005740. Swanstrom R, editor
Hill AL, Rosenbloom DIS, Siliciano JD, Siliciano RF. Insufficient evidence for rare activation of latent HIV in the absence of reservoir-reducing interventions. PLOS Pathog. 2016;12:e1005679. https://doi.org/10.1371/journal.ppat.1005679. Swanstrom R, editor
Hernandez-Vargas EA. Modeling kick-kill strategies toward HIV cure. Front Immunol. 2017; https://doi.org/10.3389/fimmu.2017.00995.
Jerome KR. Disruption or excision of provirus as an approach to HIV cure. AIDS Patient Care STDs. 2016;30:551–5. https://doi.org/10.1089/apc.2016.0232.
Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012;86:8920–36. https://doi.org/10.1128/JVI.00052-12.
Stone D, Kiem HP, Jerome KR. Targeted gene disruption to cure HIV. Curr Opin HIV AIDS. 2013;8:217–23. https://doi.org/10.1097/COH.0b013e32835f736c.
Roychoudhury P, De Silva Feelixge HS, Pietz HL, Stone D, Jerome KR, Schiffer JT. Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases. J Antimicrob Chemother. 2016:dkw104. https://doi.org/10.1093/jac/dkw104.
Lebbink RJ, De Jong DCM, Wolters F, Kruse EM, Van Ham PM, Wiertz EJHJ, et al. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep. 2017;7:1–10. https://doi.org/10.1038/srep41968. Nature Publishing Group
Brodin J, Zanini F, Thebo L, Lanz C, Bratt G, Neher RA, et al. Establishment and stability of the latent HIV-1 DNA reservoir. elife. 2016;5 https://doi.org/10.7554/eLife.18889.
Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 2014;10 https://doi.org/10.1371/journal.ppat.1004010.
Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, et al. Ongoing HIV replication during ART reconsidered. Open Forum Infect Dis. 2017;4 https://doi.org/10.1093/ofid/ofx173.
Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012;18:1378–85. https://doi.org/10.1038/nm.2892.
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, et al. Lorenzo-Redondo et al. reply. Nature. 2017;551:E10. https://doi.org/10.1038/nature24635.
Yin L, Hu S, Mei S, Sun H, Xu F, Li J, et al. CRISPR/Cas9 inhibits multiple steps of HIV-1 infection. Hum Gene Ther. 2018; https://doi.org/10.1089/hum.2018.018.
Yin C, Zhang T, Qu X, Zhang Y, Putatunda R, Xiao X, et al. In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models. Mol Ther. 2017;25:1168–86. https://doi.org/10.1016/j.ymthe.2017.03.012.
Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012;28:1647–9. https://doi.org/10.1093/bioinformatics/bts199.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. https://doi.org/10.1093/bioinformatics/btu170.
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9. https://doi.org/10.1038/nmeth.1923.
Crooks GE. WebLogo: a sequence logo generator. Genome Res. 2004;14:1188–90. https://doi.org/10.1101/gr.849004.
Schneider TD, Stormo GD, Gold L, Ehrenfeucht A. Information content of binding sites on nucleotide sequences. J Mol Biol. 1986;188:415–31. https://doi.org/10.1016/0022-2836(86)90165-8.
Finak G, Frelinger J, Jiang W, Newell EW, Ramey J, Davis MM, et al. OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysis. PLoS Comput Biol. 2014;10:e1003806. https://doi.org/10.1371/journal.pcbi.1003806.
Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82 https://doi.org/10.18637/jss.v082.i13.
Holm SA. Simple sequentially Rejective multiple test procedure. Scand J Stat. 1979;6:65–70. https://doi.org/10.2307/4615733.
Jaafoura S, De Goër De Herve MG, Hernandez-Vargas EA, Hendel-Chavez H, Abdoh M, Mateo MC, et al. Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+memory T cells. Nat Commun 2014;5. https://doi.org/10.1038/ncomms6407.
Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59:1312–21. https://doi.org/10.1093/cid/ciu585.
Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540–51. https://doi.org/10.1016/j.cell.2013.09.020. Elsevier Inc
This work was funded in part by an NIH/NIAID grant UM1 AI126623 (K. Jerome; HP Kiem, co-PIs) and NIH/NIAID University of Washington Center for AIDS Research grant P30 AI 027757-28 (K. Holmes, PI/K. Jerome Director, Co-investigator).
The code used for analysis and visualization, along with supporting data, are available on Github at http://github.com/proychou/CRISPR and FlowRepository at https://flowrepository.org/id/FR-FCM-ZYHR. Additional data are presented in Supplementary Tables, and external data sources have been cited within the text.
Department of Laboratory Medicine, University of Washington, Seattle, USA
Pavitra Roychoudhury
& Keith R. Jerome
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
Harshana De Silva Feelixge
, Daniel Reeves
, Bryan T. Mayer
, Daniel Stone
, Joshua T. Schiffer
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA
Joshua T. Schiffer
Department of Medicine, University of Washington, Seattle, USA
Search for Pavitra Roychoudhury in:
Search for Harshana De Silva Feelixge in:
Search for Daniel Reeves in:
Search for Bryan T. Mayer in:
Search for Daniel Stone in:
Search for Joshua T. Schiffer in:
Search for Keith R. Jerome in:
PR, HDSF, DS, and KRJ conceptualized the project. PR, DR, BTM, and HDSF performed the data analysis. DR and JTS designed the mathematical model. HDSF and DS designed and performed the experiments. PR and HDSF drafted the manuscript with contributions from all other authors. All authors read and approved the final manuscript.
Correspondence to Keith R. Jerome.
Table S1. (A) Correlation between predicted activity and target site conservation. (B) Correlation between measured and predicted activity. (C) Correlation between measured activity and target site prevalence. Table S2. List of highly conserved, subtype-specific triplet/paired gRNAs. Table S3. Analysis of the number of guides needed to target all available LANL sequences for LTR, gag, and pol for group M and subtypes A–C. Table S4. GFP knockdown with candidate guides tested using fluorescent reporter. Table S5. Sequences used in intra-host analysis. Table S6. Guides from globally conserved list (using LANL sequences) that have matches in patient sequence. (XLSX 59 kb)
Figure S1. (A) gRNAs were selected for functional testing based on the number of sequences targeted in a global group- or subtype-level alignment either singly, in pairs or triplets (B) amino acid sequence for the N-terminus of each LTR-reporter GFP fusion construct. M group, subtype A, subtype B, and subtype C reporter amino acid sequences are aligned for each of the 4 reporter constructs. The sequence for eGFP begins with the sequence VSKGEELFT. (C) Transfection efficiency shown in terms of percentage of mCherry+ cells in each treatment. (D) Absolute numbers of mCherry+GFP+ cells in each treatment. (EPS 498 kb)
Figure S2. (A) Flowchart showing processing steps for intra-host deep-sequence data. (B) Target site depth based on number of reads overlapping the target site in an alignment for 4 patients with deep-sequence data. Black dots indicate outlier target sites (outside 1.5 × IQR), and target sites are grouped and colored according to which consensus sequence they were identified from (the group- or subtype-level consensus from LANL alignments, or from the patient's HIV consensus sequence). (EPS 246 kb)
Figure S3. (A) Three hypothetical distributions of quasispecies abundance in the HIV reservoir. In each case, the total size of the reservoir (number of infected cells) is the same (L = 106), but the average number of cells in a quasispecies, or "log10 clone size," is μ = 102, 103, 104, respectively. Quasispecies abundances are drawn from a log-normal distribution with variance σs = μs in each case. The distributions match simulations in (B) by color. (B) Simulations of total reservoir clearance assuming suppressive cART and hypothetical CRISPR treatment of efficacy ϵ and coverage proportion ρ. Each colored line matches the respective distribution in (A). Simulations with smaller average clone sizes gave similar results. The dashed line represents a conservative HIV cure threshold (2000-fold decrease) taken from the literature. Coverage proportion is much more important that efficacy in reducing reservoir size—compare top right panels (low proportion covered, high efficacy) to bottom left panels (high proportion, low efficacy). Low efficacy can additionally be surmounted by more dosing, but HIV's large diversity remains the largest barrier to cure with this intervention. (EPS 561 kb)
Supplementary methods: c reporter design. (DOCX 1641 kb)
Roychoudhury, P., De Silva Feelixge, H., Reeves, D. et al. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biol 16, 75 (2018) doi:10.1186/s12915-018-0544-1
Endonucleases
Latent reservoir
Viral genetic diversity


text:
Diversity & equality in business
The answer is not written in the wind
With the North Sea energy bounty gone, ministers face chilling reality this winter
Larry Elliott, economics editor
Sun 23 Oct 2005 19.18 EDT First published on Sun 23 Oct 2005 19.18 EDT
Remember the three-day week? It was such a long time ago that Tony Blair was an Oxford undergraduate and the Tory Tony Blair - David Cameron - was seven. Industry, though, is worried that we could be heading right back to 1973-74 because a tough winter will lead to such severe shortages of power that the only way the government will be able to ensure the public keeps warm is by pulling the plug on business.
Energy, according to Sir Digby Jones, is now the biggest issue troubling his CBI members - bigger than the state of the economy, pensions or the threat from China. What is more, it goes far deeper than whether power supplies to industry are disrupted this winter, damaging though that would be.
The crisis has a number of strands. One is that energy is becoming dearer. Sir Digby says that his members are paying double what they were two years ago; at a time of cut-throat competition, business is forced to absorb that increase in its profit margins.
A second is that the days when Britain was self-sufficient in energy are coming to an end. Oil exports and imports are now broadly in balance, while gas is already being imported. Sir Digby's worry about this winter - contested by ministers and some in the energy industry - is that inadequate planning has meant there is not enough storage capacity for imported gas, and a cold snap lasting a week or two would exhaust reserves.
Within a couple of years this problem will be overcome with the opening of a pipeline from Norway and other new sources of imports. But this will only help to keep existing gas capacity going; it will not solve the problem of replacing clapped-out coal and nuclear plants. The reason gas has become crucial is that between now and 2020 a chunk of Britain's coal-fired and most of its nuclear power stations will have closed - and they currently account for more than 50% of power generation. In the medium term, the UK will rely heavily on gas from Russia and the Middle East, with all that means in terms of vulnerability to political instability and higher prices.
Finally, there is the question of climate change and Britain's obligations to meet its pledges to cut carbon emissions. The plan is to increase the power generated by renewable sources to 20% of total output by 2020. In practice, the government is banking on a huge increase in wind power, considered by many energy experts to be absurdly optimistic. Denmark, for example, generates 16% of national demand from wind power and is seen as the example for Britain to follow.
One of the main drawbacks, however, is that sometimes the wind doesn't blow and at other times it blows so hard that the turbines have to be shut down. The really cold spells in winter tend to be associated with high pressure and little or no wind. In those circumstances, you either have alternative sources of supply - in Denmark's case hydroelectric power from Norway and Sweden - or you have a big problem. The more wind power you have, the more back-up you need, and if that back-up capacity is only being used part of the time it will be expensive to build and could be more environmentally damaging to run.
The Renewable Energy Foundation concluded that "over-deployment of randomly intermittent renewables, such as wind power, to the exclusion of firm generating plant, such as tidal and biomass, may actually make the overall system more dependent, not less, on fossil systems". The energy consultant Hugh Sharman puts it even more starkly. In a forthcoming article for the Institution of Civil Engineering, he says wind power will "do nothing" to offset the inevitable loss of firm generating capacity, and £40bn-£50bn needs to be spent by 2020 on new generating capacity from a diversity of sources. "At the time of writing, and considering that almost nothing of substance is being considered, this is a frightening challenge," he says.
So what next? The first option is the status quo: expand the use of gas and wind power. That does not sound especially sensible, and there is evidence that the government is uneasy about having all its eggs in two baskets. That's why the second option - a return to nuclear - is gaining support. The government's chief scientist, Sir David King, said last week that an expansion of nuclear power might be needed both to meet environmental targets and to avoid over-reliance on Russian gas. He is one of the prime minister's most trusted advisers, so his words carry weight. The downside of the nuclear option is that it is expensive, solves one environmental threat by creating another, has problems with waste disposal and plant decommissioning and, unless the government can circumvent planning laws, would take a long time to bring on stream.
A third option would be to approach the problem from the other end. At present the assumption is that the supply of energy has to increase to meet ever-rising demand. The alternative would be to say that we already consume too much energy and the aim should be to cut back. For this to happen, there would need to be a proper, all-embracing international agreement, including both the developed and the developing world, not the botched job that led to the limited Kyoto deal.
By far the best worked-out method of securing a global accord is the contraction and convergence model, which sets a ceiling on greenhouse gas emissions consistent with preventing global warming and establishes a timetable for apportioning the right to pollute equally to everybody on the planet. A year or so ago, campaigners for the model thought they were getting somewhere with the government, but ministers appear to have gone cold on the idea, perhaps because spelling out the facts to the public is politically unpalatable.
The Engineering Employers Federation today calls for an expansion of nuclear power as part of a balanced energy portfolio. Its director general, Martin Temple, says: "Energy is now right at the top of the agenda and there is no time to lose in putting in place a long-term strategy that will provide a competitive, reliable and secure supply, and generate significant reduction in emissions. Failure to do so will mean relying on new technology and energy efficiency to come to our aid, which alone is unlikely to deliver on any of these fronts."
There are no soft options. After the last three-day week we took the bounty from the North Sea and blew it. After three fat decades, a reality check looms.
larry.elliott@theguardian.com

redpajama_set_name: RedPajamaCommonCrawl


Everything I'm good at today I sucked at in the past.
Every problem I've ever had in the past eventually worked out, one way or the other.
Every time I screwed up…even when I screwed up big time, I eventually landed on my feet. Perhaps not in the place I'd hoped, but I landed, to soldier on another day.
Why should it be any different with the challenges I face today?
Important because Every doubt or fear or challenge you face today will eventually resolve and evaporate into a memory. Not like wishful positive thinking, more like a profound, intelligent awareness that this too shall pass.


Another sporty Bing Map App got released yesterday, this time for cycling fans. Le Tour de France runs from Saturday July 3rd to Sunday July 25th 2010. The 97th Tour de France will be made up of 1 prologue and 20 stages and will cover a total distance of 3,642 kilometers. Now you can not only follow it on the Tour De France site or television but also on the Bing 2010 Tour de France map app.
More information can be found on the Bing maps blog.
Nu ser det godt nok ud til at Bjarnes hold lukker næste år, men I det mindste kan man nyde årets Tour de France med Bing.


text:
Arts+CultureFeature
12October 2015
TextLouisa Newton
Goodyn Green's "Between Sheets" seriesGoodyn Green
The porn festival shifting attitudes to sex on screen
PorYes is a female-led, sex-positive event that wants to celebrate fair porn and make it less masculine
Being a vibrant haven for diversity and culture, it wouldn't make sense to have Europe's first feminist porn movie award ceremony anywhere else but Berlin. The city has welcomed the PorYes awards with open arms since 2009, acknowledging that "feminist pornography" or "sexpositive feminism" is also a counterculture; as it repels the mainstream "norms'"of erotica by confronting sexism in pornography.
Advocating the positive portrayal of sexuality, PorYes celebrates and also embraces contemporary attitudes within the adult film industry, making way for the establishment of a much needed sex-positive shift in erotic culture. Taking place every two years, the 2015 event will occupy take place between October 17-19 at the Hackesche Höfe Kino, an independent arthouse cinema in Berlin Mitte.
"The idea of PorYes emerged around the last millennium when more and more women filmed, produced and distributed their own erotica particularly as a form of protest against the malestream sexism and racism" explains Dr Laura Mérritt, a sexpert and PorYes juror. "From the 1960s on, the sex positive women's movement supported another language for sex and especially positive words and pictures for female sexuality. This movement becomes bigger and more popular as the public interest in feminist porn increases. PorYes has reached the media by bringing together feminism and porn which has been thought by some people only as an opposition. As we live in a pornographic society where you can barely escape porn sexism, people are interested in alternatives in erotic pictures and also in sexual knowledge. PorYes satisfies the demand for positive and fair porn."
PorYes sets to convert a public space into a manifestation of women's pornography, not only promoting but also forming a sex-positive shift in erotic culture. Presenting a political and progressive subsidiary to the "old boys" productions in porn, PorYes and Dr Laura Mérritt are ready to send a groundbreaking gender-political message and stimulate discussion. "I tell my daughters to sexperiment whatever they want to, and first to make sure a safe space and a safe communication with all participants is given," says Merritt. "Always being able to say no and stop is part of the play, learning to ask and give feedback means sexual competence."
Goodyn Green's "Between Sheets"Goodyn Green
Now about to celebrate its fourth series of events, this year's PorYes awards are set to be as diverse as ever, with nominees ranging from erotica imagists and porn stars to photographers and filmmakers. "Our nominees are from different ages and cultures and profile in their very individual style of deconstructing gender and sex stereotypes," says Mérritt. "We love to see sexual communication, safer sex, slow porn or anything that is sex-positive, consensual and supports diversity. This year our focus is on body norms – nominees like Buck Angel and Jiz Lee are famous for depicting genderqueerness."
Berlin-based Dutch photographer and current nominee Goodyn Green added, "I believe that the PorYes awards is helping to change many people's view on porn from negative to positive by putting a focus on feminist and queer porn, they show it from another perspective which sadly is still unknown to most people." Regarding her interest in capturing androgyny in her work, Goodyn says: "In the queer world I'm surrounded by androgynous people, including myself, so it just comes naturally when I include androgyny in my photographic work. I think there generally is a larger focus on dividing the roles among the protagonists in lesbian porn, in either butches or femmes. Personally, I would like to see more androgyny displayed."
'A main focus on male ejaculation in women's faces as the sexual climax is reducing the "masculine" as the main repertoire of sex practices'
Recent studies have shown that contemporary women's attitudes towards erotica are changing, with a high documentation of discriminatory behaviour and violence within pornograhy. PorYes seeks to carry on the transformation to revolutionise healthy and consensual sexual experimentation, stemming from the "social movements and, primarily, the women's movement, which has changed sexual ethics over the past 35 years and introduced a new set of ethics in negotiation."
Mérritt says that "the message to the old boys of pornography is diversity. There are many ways to show lusty and respectful, consensual and realistic sexuality between different genders. A main focus on male ejaculation in women's faces as the sexual climax is reducing the "masculine" as the main repertoire of sex practices. Fair porn is an option to think about and humour is very relaxing for all."
"Tons of people tell me, women and men alike, that the concept of 'feminist porn' is a brain-breaker for them. How can porn be feminist?" asks Jennifer Lyon Bell, director of Blue Artichoke films and current PorYes nominee. "But once we get to talking, most people intuitively grasp how fulfilling it could be to see porn that's ethically made and shows women's sexuality in a realistic way, even if there's lots of fantasy involved. For me this kind of porn feels completely natural and normal; it's just plain more fun for me to watch. I like getting other people to feel that way too. Thanks in part to the PorYes European Feminist Porn Award openly celebrating this kind of porn diversity, slowly the mainstream media seem to be catching on that there is no one monolith called 'PORN'. There are lots of kinds of porn, and some of them are not only fun but make you feel good in a deeper way."
PorYes events include the award ceremony, industry talks and panel discussions, plus a party with DJ Third_Space. Tickets can be purchased online, with discounts handed to those holding a "Porn Queen Card" who distinguish themselves as revolutionary supporters of the sex positive network. Porn star or not, PorYes invites like-minded guests to converse in celebrating an area of pornography that's widely overlooked and often undervalued.
Arts+CultureFeatureNewsSexpornBerlin


Vaccination rates plummeted and infection rates of preventable diseases skyrocketed when the world started to believe vaccines caused autism, but the rapid rise of autism rates tell a different story. An infographic has been designed to inform parents and other skeptics of the truth behind the relationship between vaccinations and autism and why it even started in the first place.
Why did people begin thinking that childhood vaccines such as the measles, mumps, and rubella (MMR) shots, cause autism? The birth of this falsehood was fathered by Dr. Andrew Wakefield, a British surgeon and medical researcher who published a study in The Lancet in 1998 claiming to have found a connection between vaccines and the onset of autism.
Autism is a brain development disorder that causes social, cognitive, and communication impairements. It can range from very mild to very severe and does not discriminate by ethnicity or socioeconomic groups, as it can happen to any child. Currently, research points to a genetic predisposition of autism in addition to an environmental component. The sharp rise in autism diagnosis over the last 20 years cannot be attributed solely to genetics, so research presses on, according to the National Autism Association.
When the paper was published it spread like wildfire across the world, instilling fear in parents and pediatricians alike. But after a decade-long investigation of unraveling Wakefield's research and studies of 25,782,500 children, researchers concluded there was no causal relationship between vaccines and autism. Wakefield's paper was retracted in 2010 due to the paper's scientific limitations, which were not based on statistics, lacked a control group, relied on people's memories for vaccination records, vague conclusions not based on statistical outcomes, and the use of such a small group of 12 children as test subjects.
Researchers scrambled to find the answer, and by 1999 they had conducted a study using 500 children. No connection between autism and vaccines was found. But just to make sure, scientists went back to the drawing board and two years later another study was published using 10,000 children. Studies using 537,000 children were evaluated in Denmark, and then an additional 535,000 children were studied in Finland. Not only could no one reproduce Wakefield's findings, but they couldn't even find a link anywhere in their own research.
In 2012, a meta-analysis was conducted using 14,700,000 million children. No link to autism was found in any of the 58 studies researchers analyzed, yet the leftover of Wakefield's small but dramatized findings have left millions of children unvaccinated.
Today, one out of four parents believes vaccines cause autism in otherwise healthy children, and there has consequently been a steady decline in vaccinations. In the past 20 years, vaccines given to infants and young children will prevent 322 million illnesses, 21 million hospitalizations, and 732,000 deaths throughout their lifetime, according to the Centers for Disease Control and Prevention.
Yet, there were nearly 50,000 people in the United States who contracted whooping cough, which caused 20 deaths in 2012 alone. Whooping cough is a highly contagious respiratory tract infection that is completely preventable if a child is vaccinated. Before Wakefield's paper was published, there were only 2,900 cases throughout the 1980s. It's currently on the rise, and an additional 5,400 children in California were reported to have confirmed whooping cough cases as of July 8.
There are new and underutilized vaccinations waiting to treat children, if only their parents were informed enough to understand they're non-threatening. They have the power to prevent nearly four million deaths of children five years and young by 2015.


Massachusetts Fire Pit Laws pictures bottom is part of the post in Massachusetts Fire Pit Laws gallery. Related with Fire Pits category.
Summer season is near and an a fire pits is something which almost all people can use, the outdoor fire pits works extremely well with cold nights and also your own personal backyard a little more particular for your guests and for your self seeing that you enjoy your back garden as well as outdoor space using a nice fire pits.
Presently there are a lot of different fire fit choices today, you definitely does not need to build your own fire pits, you could find a fire pits within many home shops, as well as there are even a number of special designers that do the job with fire pits.
For Fire Pits, You can find many ideas on the topic massachusetts, fire, laws, pit, and many more on the internet, but in the post of Massachusetts Fire Pit Laws we have tried to select the best visual idea about Fire Pits You also can look for more ideas on Fire Pits category apart from the topic Massachusetts Fire Pit Laws.
This post published on Wednesday, April 25th, 2018 . Read How To Start A Fire In A Fire Pit or find other post and pictures about Fire Pits.


text:
This site is 100% ad supported. Please add an exception to adblock for this site.
+ Create A Deck
Other sites by Rob:
Pirate Game
Domain Name Generation
decks >
china >
A&DD midterm Wed Apr 09 2008 20:26:59 GMT+0000 (UTC)
Cultural Studies Thu Jan 17 2008 14:32:52 GMT+0000 (UTC)
Chapter 24 - The Beginnings of Colonial Nationalism Tue Apr 22 2008 19:46:15 GMT+0000 (UTC)
China - History Tue Nov 13 2007 19:23:54 GMT+0000 (UTC)
China Test Review Thu Mar 06 2008 20:58:15 GMT+0000 (UTC)
Intro to Chinese History Midterm: Son of Sat Feb 16 2008 18:10:15 GMT+0000 (UTC)
HH 10 Theology- Exam 1 Fri Jan 18 2008 08:16:27 GMT+0000 (UTC)
japan! Thu May 29 2008 19:31:20 GMT+0000 (UTC)
History, Industrial Revolution Mon Feb 25 2008 01:34:57 GMT+0000 (UTC)
Global Ministries 101 Test Wed Mar 19 2008 00:58:22 GMT+0000 (UTC)
Taoism, Confucianism & Shinto Thu Nov 13 2008 08:44:41 GMT+0000 (UTC)
Imperial Russia 1 Tue Oct 02 2007 14:19:57 GMT+0000 (UTC)
imperial-russia
World History pt. 1 Wed Jul 23 2008 23:01:02 GMT+0000 (UTC)
Intro to Chinese History Midterm Sat Feb 16 2008 18:10:18 GMT+0000 (UTC)
Confucianism Thu Nov 13 2008 09:36:51 GMT+0000 (UTC)
AP world 1st semester Mon May 14 2018 16:36:52 GMT+0000 (UTC)
whap
differention
shang
history111final Sun Apr 27 2008 21:52:05 GMT+0000 (UTC)
AP World History Ch 4-7 Test Thu Sep 18 2008 16:25:31 GMT+0000 (UTC)
AP Environmental Science Tue May 22 2007 11:12:14 GMT+0000 (UTC)
microbiopt3 Thu Mar 26 2009 00:23:38 GMT+0000 (UTC)
4511 cards
Sign Language Tue Mar 28 2006 22:07:01 GMT+0000 (UTC)
Geography Final Thu May 07 2009 23:19:11 GMT+0000 (UTC)
chmistry
UH history Exam Mon May 18 2009 20:41:50 GMT+0000 (UTC)
history - american studies Thu Jan 15 2009 22:18:10 GMT+0000 (UTC)
k-201 final Mon Dec 15 2008 22:59:56 GMT+0000 (UTC)
psych 305 midterm 1 Sat Oct 10 2009 22:20:42 GMT+0000 (UTC)
pwer-of-continuity
Ancient China 1 Wed Oct 21 2009 11:34:06 GMT+0000 (UTC)
Civilization Awakens from Darkness Mon Sep 14 2009 11:15:02 GMT+0000 (UTC)
WGS Midterm Thu Oct 15 2009 01:13:40 GMT+0000 (UTC)
history qt 1 Tue Oct 27 2009 21:07:55 GMT+0000 (UTC)
MGCR 382 - International Business (Midterm) Tue Feb 12 2013 01:35:27 GMT+0000 (UTC)
Psych 315 Final Fri Dec 04 2009 11:10:15 GMT+0000 (UTC)
conquering the islands Thu Feb 08 2007 11:11:23 GMT+0000 (UTC)
completion of the imperial state Wed Feb 07 2007 16:27:09 GMT+0000 (UTC)
World History Mid-Term Exam Tue Oct 27 2009 18:54:02 GMT+0000 (UTC)
Religion and Society Sun Aug 31 2008 12:09:55 GMT+0000 (UTC)
206 Exam IV (Group Dynamics Section) Fri Jun 15 2007 11:01:29 GMT+0000 (UTC)
History 101 Final Terms and Dates Fri Dec 11 2009 11:25:56 GMT+0000 (UTC)
Ch. Reviews Mon May 14 2018 16:36:27 GMT+0000 (UTC)
World History: Patterns of Interaction, Chapter 7 Mon May 14 2018 16:36:27 GMT+0000 (UTC)
Vocabulary List Number 14 Mon May 14 2018 16:36:29 GMT+0000 (UTC)
USMA HI107 ID/SIG terms WPR#1 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
The Mongols Mon May 14 2018 16:36:34 GMT+0000 (UTC)
World Geography: C41/ E.&SE Asia &C42China,Taiwan&Mongolia Mon May 14 2018 16:36:35 GMT+0000 (UTC)
Mr.Mccollaum's chapter 13 1n2+4,and 14-1 Mon May 14 2018 16:36:35 GMT+0000 (UTC)
Locations Mon May 14 2018 16:36:36 GMT+0000 (UTC)
NY Bar Exam Review - Secured Transactions/Commercial Paper Mon May 14 2018 16:36:42 GMT+0000 (UTC)
commercialpaper
lisacoyle16
Hinduism/Buddhism Mon May 14 2018 16:36:46 GMT+0000 (UTC)
Micro-Lect6: +RNA viruses Mon May 14 2018 16:36:55 GMT+0000 (UTC)
6--rna
bio lecture 20 Mon May 14 2018 16:37:00 GMT+0000 (UTC)
Spanish I - Chapter 1 Vocabulary Mon May 14 2018 16:37:04 GMT+0000 (UTC)
Chinese Characters - 001 Mon May 14 2018 16:37:11 GMT+0000 (UTC)
Mammalogy Lecture 5 Mon May 14 2018 16:37:12 GMT+0000 (UTC)
Week1 Team Responsibilities/Infection Control Mon May 14 2018 16:37:12 GMT+0000 (UTC)
responsibilities-infecti
History October Mon May 14 2018 16:37:14 GMT+0000 (UTC)
IsCiv from lec 4 of "HAI" [pp. 36-37,40-41] Mon May 14 2018 16:37:17 GMT+0000 (UTC)
--quot;hai--quot;
isciv
-quot;hai-quot;
Ultimate Italian Lezione 4 Mon May 14 2018 16:37:19 GMT+0000 (UTC)
Cross Cultural Management Mon May 14 2018 16:37:20 GMT+0000 (UTC)
Innis Woman Warrior ch 1/2 Mon May 14 2018 16:37:21 GMT+0000 (UTC)
Gov. Chp. 1 Mon May 14 2018 16:37:23 GMT+0000 (UTC)
J2 Kanji vocabualry Chapter 5-1 Mon May 14 2018 16:37:23 GMT+0000 (UTC)
lynbrookhsj2
foreign-language
Korean Vocab B Sat Jul 10 2010 07:18:17 GMT+0000 (UTC)
SK- ì—° Chapter 1 Sat Apr 07 2012 03:02:55 GMT+0000 (UTC)
Earth Science Facts Mon May 14 2018 16:36:16 GMT+0000 (UTC)
middle-school
Governments Mon May 14 2018 16:36:19 GMT+0000 (UTC)
AMH&G I Final Mon May 14 2018 16:36:19 GMT+0000 (UTC)
U.S.History 1 Mon May 14 2018 16:36:19 GMT+0000 (UTC)
european-history
AP World History 14-16 Mon May 14 2018 16:36:19 GMT+0000 (UTC)
AP WH 17-19 Mon May 14 2018 16:36:20 GMT+0000 (UTC)
WOW 6 Mon May 14 2018 16:36:20 GMT+0000 (UTC)
geography2 Mon May 14 2018 16:36:20 GMT+0000 (UTC)
Nursing - Healthcare of Older Adult Mon May 14 2018 16:36:20 GMT+0000 (UTC)
Ancient China Mon May 14 2018 16:36:21 GMT+0000 (UTC)
bills cards Mon May 14 2018 16:36:22 GMT+0000 (UTC)
World Civilizations Midterm Review Mon May 14 2018 16:36:22 GMT+0000 (UTC)
Social Studies Ch 5 Mon May 14 2018 16:36:22 GMT+0000 (UTC)
Huckleberry Finn Mon May 14 2018 16:36:22 GMT+0000 (UTC)
World History Midterm Mon May 14 2018 16:36:23 GMT+0000 (UTC)
Five in a Row Volume 1 Mon May 14 2018 16:36:23 GMT+0000 (UTC)
Samurai Study Cards Mon May 14 2018 16:36:23 GMT+0000 (UTC)
Global History Mon May 14 2018 16:36:23 GMT+0000 (UTC)
SS ESSAY QUESTIONS Mon May 14 2018 16:36:23 GMT+0000 (UTC)
History-Pressler Mon May 14 2018 16:36:24 GMT+0000 (UTC)
da-vinci
WC Ch. 27 Mon May 14 2018 16:36:24 GMT+0000 (UTC)
president2 individual Mon May 14 2018 16:36:24 GMT+0000 (UTC)
american-history
Anthro 102 Mon May 14 2018 16:36:25 GMT+0000 (UTC)
Japanese History 10,000 BC -1333 AD Mon May 14 2018 16:36:25 GMT+0000 (UTC)
Vocab review for final exam Mon May 14 2018 16:36:25 GMT+0000 (UTC)
World History I SOL Review Mon May 14 2018 16:36:25 GMT+0000 (UTC)
World History review Mon May 14 2018 16:36:25 GMT+0000 (UTC)
Western Civ 2 Mon May 14 2018 16:36:26 GMT+0000 (UTC)
History, Section 4 Mon May 14 2018 16:36:26 GMT+0000 (UTC)
04Chinese philosophies Mon May 14 2018 16:36:26 GMT+0000 (UTC)
Chinese Dynasties Mon May 14 2018 16:36:27 GMT+0000 (UTC)
World geography Chapter 8 Mon May 14 2018 16:36:27 GMT+0000 (UTC)
RN103 exam 2 Mon May 14 2018 16:36:27 GMT+0000 (UTC)
unit 3 exam Mon May 14 2018 16:36:27 GMT+0000 (UTC)
History of Islam Mon May 14 2018 16:36:27 GMT+0000 (UTC)
MEGASTHENES Mon May 14 2018 16:36:28 GMT+0000 (UTC)
Six Billion and Beyond Movie Mon May 14 2018 16:36:28 GMT+0000 (UTC)
presidents 1-17 2 Mon May 14 2018 16:36:28 GMT+0000 (UTC)
History Chapter 7 Terms and Names Mon May 14 2018 16:36:29 GMT+0000 (UTC)
Chapter 9 Test Mon May 14 2018 16:36:29 GMT+0000 (UTC)
18Chinese Economic System Patterns Mon May 14 2018 16:36:29 GMT+0000 (UTC)
20Japan Economics Unit Part 1 Mon May 14 2018 16:36:29 GMT+0000 (UTC)
History, Section 13 Mon May 14 2018 16:36:29 GMT+0000 (UTC)
22Matthew C. Perry and Meiji Modernization Mon May 14 2018 16:36:30 GMT+0000 (UTC)
1100 words week 19--day 3*4 Mon May 14 2018 16:36:30 GMT+0000 (UTC)
23Japan's First Modernization (Meiji) Mon May 14 2018 16:36:30 GMT+0000 (UTC)
SOC101 Mon May 14 2018 16:36:30 GMT+0000 (UTC)
prez test 2 Mon May 14 2018 16:36:30 GMT+0000 (UTC)
Tisdale presidents test Mon May 14 2018 16:36:30 GMT+0000 (UTC)
HUSTON-AP US GOVT CHAP 19 Mon May 14 2018 16:36:30 GMT+0000 (UTC)
Reformation and Religious Wars Mon May 14 2018 16:36:30 GMT+0000 (UTC)
USAP Chapters 1 - 6, 25 - 29 Mon May 14 2018 16:36:30 GMT+0000 (UTC)
Virology - 2 Mon May 14 2018 16:36:31 GMT+0000 (UTC)
SS Ch. 28 and sect. 1+2 of 29 Mon May 14 2018 16:36:31 GMT+0000 (UTC)
Social Studies Assessment-WORLD WAR I/II Mon May 14 2018 16:36:31 GMT+0000 (UTC)
AP World History 2 Mon May 14 2018 16:36:32 GMT+0000 (UTC)
Early Modern Times Mon May 14 2018 16:36:32 GMT+0000 (UTC)
1920's - 1980's Mon May 14 2018 16:36:32 GMT+0000 (UTC)
ch. 1 stearns --- civilization Mon May 14 2018 16:36:32 GMT+0000 (UTC)
pep words Mon May 14 2018 16:36:32 GMT+0000 (UTC)
World History to 1550 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
World History since 1550 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
Chapt.1 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
Spanish 101 2 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
World History Chap. 2 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
Unit 1 test Mon May 14 2018 16:36:33 GMT+0000 (UTC)
EXAM #2 (Soc. 335: Drug and Alcohol Abuse) Mon May 14 2018 16:36:33 GMT+0000 (UTC)
ICC - Human Growth and Dev. Chapter 6 Mon May 14 2018 16:36:33 GMT+0000 (UTC)
gross-motor-skills
Chapter 11 - CHINA Mon May 14 2018 16:36:34 GMT+0000 (UTC)
arthistory
Chapter 12 - Japan Mon May 14 2018 16:36:34 GMT+0000 (UTC)
American History Midterm Mon May 14 2018 16:36:34 GMT+0000 (UTC)
UTexas Vocabulary 2 Mon May 14 2018 16:36:34 GMT+0000 (UTC)
utexas
Dar Al Islam Mon May 14 2018 16:36:34 GMT+0000 (UTC)
World History- India and China Mon May 14 2018 16:36:34 GMT+0000 (UTC)
presentations for plant bio Mon May 14 2018 16:36:34 GMT+0000 (UTC)
Lecture 21: Viscerotropic and Neurotropic Viral Diseases Mon May 14 2018 16:36:35 GMT+0000 (UTC)
History Chapter 12 Flashcards Mon May 14 2018 16:36:35 GMT+0000 (UTC)
HSC2100 Exam #3 Mon May 14 2018 16:36:35 GMT+0000 (UTC)
generalpathology
Geography Finals Terms Mon May 14 2018 16:36:35 GMT+0000 (UTC)
Osiris Mon May 14 2018 16:36:35 GMT+0000 (UTC)
World Geography Final- December Mon May 14 2018 16:36:35 GMT+0000 (UTC)
American History Final Mon May 14 2018 16:36:35 GMT+0000 (UTC)
civilization101 final exam Mon May 14 2018 16:36:35 GMT+0000 (UTC)
504 Exam Mon May 14 2018 16:36:35 GMT+0000 (UTC)
World Geography 6R Semester Exam Mon May 14 2018 16:36:35 GMT+0000 (UTC)
World Geography Finals Mon May 14 2018 16:36:35 GMT+0000 (UTC)
World History - Unit 3 Mon May 14 2018 16:36:36 GMT+0000 (UTC)
Ancient China, Japan, & Africa Mon May 14 2018 16:36:36 GMT+0000 (UTC)
MEDICAL NURSING I - Breed Identification Mon May 14 2018 16:36:36 GMT+0000 (UTC)
MOROSI FINAL EXTRA LITTLE STUFF Mon May 14 2018 16:36:36 GMT+0000 (UTC)
World History Midterm 2 Mon May 14 2018 16:36:36 GMT+0000 (UTC)
The REAL history mid-term Mon May 14 2018 16:36:36 GMT+0000 (UTC)
International Relations Midterm Mon May 14 2018 16:36:36 GMT+0000 (UTC)
3majorreligions
arab-israeliconflict
foreignpolicy
historyofislam
middleeastconflict
middleeaststudies
World History Final Study Guide- Ch. 1-9 Mon May 14 2018 16:36:36 GMT+0000 (UTC)
World Cultures J Midterm Review Mon May 14 2018 16:36:37 GMT+0000 (UTC)
chpts
age of exploration bio Mon May 14 2018 16:36:37 GMT+0000 (UTC)
world geo. vocab words Mon May 14 2018 16:36:37 GMT+0000 (UTC)
Geog 100 - Test I Mon May 14 2018 16:36:37 GMT+0000 (UTC)
Japan - Test One Mon May 14 2018 16:36:37 GMT+0000 (UTC)
The Roaring Twenties Mon May 14 2018 16:36:37 GMT+0000 (UTC)
Geography Trivia Mon May 14 2018 16:36:38 GMT+0000 (UTC)
Geography Exam 2 Mon May 14 2018 16:36:38 GMT+0000 (UTC)
goooo
civ 102 midterm Mon May 14 2018 16:36:38 GMT+0000 (UTC)
instrumental lit exam 2 Mon May 14 2018 16:36:38 GMT+0000 (UTC)
Para 1 and 2 Mon May 14 2018 16:36:39 GMT+0000 (UTC)
Roman HIstory Mon May 14 2018 16:36:39 GMT+0000 (UTC)
civ 102 test 3 Mon May 14 2018 16:36:39 GMT+0000 (UTC)
cEwing.impromptu speech Mon May 14 2018 16:36:40 GMT+0000 (UTC)
cewing
lopo's extemp cards Mon May 14 2018 16:36:40 GMT+0000 (UTC)
Duchesne Speech Class Mon May 14 2018 16:36:40 GMT+0000 (UTC)
erinkramelb
SS Chapter 10 Mon May 14 2018 16:36:40 GMT+0000 (UTC)
Dos Mundos Paso C Mon May 14 2018 16:36:40 GMT+0000 (UTC)
paso-c
history finals flash-two Mon May 14 2018 16:36:41 GMT+0000 (UTC)
morse-code
World Cultures Vocabulary Terms Mon May 14 2018 16:36:41 GMT+0000 (UTC)
World Studies Events and People Mon May 14 2018 16:36:41 GMT+0000 (UTC)
final-
Sacco Ch. 7 Mon May 14 2018 16:36:41 GMT+0000 (UTC)
Psych 353 Final Mon May 14 2018 16:36:41 GMT+0000 (UTC)
global 2 Mon May 14 2018 16:36:41 GMT+0000 (UTC)
ID questions Mon May 14 2018 16:36:41 GMT+0000 (UTC)
OED "M" Mon May 14 2018 16:36:42 GMT+0000 (UTC)
Gerontology Mon May 14 2018 16:36:42 GMT+0000 (UTC)
geron
mat Mon May 14 2018 16:36:43 GMT+0000 (UTC)
Final Exam Questions Church History Mon May 14 2018 16:36:43 GMT+0000 (UTC)
U.S. Government Ch 1 vocabulary Mon May 14 2018 16:36:43 GMT+0000 (UTC)
Language Chinese frequent characters 41-55 Mon May 14 2018 16:36:43 GMT+0000 (UTC)
Kanji 33 - 48 Mon May 14 2018 16:36:43 GMT+0000 (UTC)
common1 Mon May 14 2018 16:36:44 GMT+0000 (UTC)
Bahasa Indonesia novice low vocab Mon May 14 2018 16:36:44 GMT+0000 (UTC)
Spanish Chapter 03 Vocabulary Mon May 14 2018 16:36:45 GMT+0000 (UTC)
House & Home La Casa Y El Hogar Mon May 14 2018 16:36:45 GMT+0000 (UTC)
1st quarter 7th grade Middle East Exam Mon May 14 2018 16:36:45 GMT+0000 (UTC)
socialstudies
Chapter 26: America Moves to the City, 1865-1900 from The American Pageant Mon May 14 2018 16:36:46 GMT+0000 (UTC)
College of DuPage Japanese I Vocabulary Mon May 14 2018 16:36:46 GMT+0000 (UTC)
collegeofdupage
tsubasagurei
Hist 270 Midterm - American History to 1877 Mon May 14 2018 16:36:46 GMT+0000 (UTC)
the-empire-in-transition
peace-of-paris
World History 1st Quarter Mon May 14 2018 16:36:46 GMT+0000 (UTC)


text:
Q: Avoid the same date in a column for maximum 10 times in Google Sheet I would to find a way to avoid to insert in the column A of a spreadsheet the same date for maximum 10 times, and so if in the column A there is already the same date 10 times, if a user try to insert another time the same date, a popup will alert that it is not possible.
I am trying with Apps Script writing the code below, but it works only with alphabetical values and not with dates.
Maybe I have to format something?
function onEdit(e) {
  var r = e.range;
  var s = r.getSheet();
  if(s.getName()==='Foglio1' && r.getColumn()===1) {
    var newValue = e.value;
    var b = s.getRange('A1:A');
    var bv = b.getValues();

    var count = 0;
    var flag = false;
    for(var i=0;i<bv.length;i++) {
      if(bv[i][0]===newValue)
        count++;
      if(count>10) {
        flag = true;
        break;
      }
    }

    if(flag) {
      r.setValue(e.oldValue);
      SpreadsheetApp.flush();
      SpreadsheetApp.getUi().alert('This date is already inserted 10 times');
    }
  }
}

A: For example, as a simple modification, how about using getDisplayValue as follows?
Modified script 1:
function onEdit(e) {
  var r = e.range;
  var s = r.getSheet();
  if (s.getName() === 'Foglio1' && r.getColumn() === 1) {
    var newValue = r.getDisplayValue();
    var b = s.getRange('A1:A');
    var bv = b.getDisplayValues();
    var count = 0;
    var flag = false;
    for (var i = 0; i < bv.length; i++) {
      if (bv[i][0] === newValue) {
        count++;
      }
      if (count > 10) {
        flag = true;
        break;
      }
    }
    if (flag) {
      r.setValue(e.oldValue);
      SpreadsheetApp.flush();
      SpreadsheetApp.getUi().alert('This date is already inserted 10 times');
    }
  }
}

Modified script 2:
As other method, in this modification, filter is used for counting the values.
function onEdit(e) {
  var r = e.range;
  var s = r.getSheet();
  if (s.getName() === 'Foglio1' && r.getColumn() === 1) {
    var newValue = r.getDisplayValue();
    if (newValue == "") return;
    var count = s.getRange('A1:A').getDisplayValues().filter(([a]) => a === newValue).length;
    if (count > 10) {
      r.setValue(e.oldValue);
      SpreadsheetApp.flush();
      SpreadsheetApp.getUi().alert('This date is already inserted 10 times');
    }
  }
}

References:

*

*getDisplayValue()

*getDisplayValues()

*filter()

redpajama_set_name: RedPajamaStackExchange


General Motors Diagnostic Software System 2 is the next-generation scantool and diagnostic platform General Motors has developed to support GM Global A vehicles beginning with the model year 2010.
General Motors Diagnostic Software System 2 is the new scantool and diagnostic platform General Motors has developed to support GM Global A vehicles beginning with the model year 2010.
General Motors Diagnostic Software System 2 is commonly known as GDS2. GDS2 is the new scantool and diagnostic platform General Motors has developed to support GM Global A vehicles beginning with the model year 2010.